biosimilars

基本解釋

Biosimilars are generic impersonations (although not identical copies) of biotech drugs.
生物仿制制藥是對生物技術(shù)制藥進行的非專利仿制（盡管不是完全一致的復制）。
Michael Kamarck of Merck, an American drugs firm which moved into biosimilars in 2008, thinks the barriers to entry are so great that “only a handful” of firms will be able to pull it off.
一家于2008年轉(zhuǎn)向生物仿制制藥的美國制藥公司---默克公司認為進入生物仿制制藥這個領(lǐng)域的障礙是如此之大以至于“只有幾家”公司有能力成功進入。
This will put Merck in direct competition both with generics firms, such as Teva of Israel, and with biotech giants, such as Amgen, which make the expensive products that biosimilars hope to replace.
默克將因此與仿制藥公司（比如以色列的Teva）和生物技術(shù)業(yè)的巨頭（比如Amgen）直接競爭，生物仿制品有望替代這些公司生產(chǎn)的昂貴產(chǎn)品。

In the future, new analytical methods will facilitate the development and regulatory approval of biosimilars.
FORBES: Do You Think 'Biosimilars' Will Reduce Healthcare Expenditures? Think again.
Concurrently, over the past few years the broader view of the biosimilars market has changed.
FORBES: Gamekeeper or Poacher? - Big Pharma's Stance on Biosimilars
When these arguments were made during the debate over creating a biosimilars pathway, they were often dismissed.
FORBES: Blood Drug Woes Could Weigh on FDA and its Approval of New, Copycat Biologic Medicines